ClinicalTrials.gg
CompletedNCT04311424Updated Mar 24, 2023Results posted

Study of Tirzepatide in Healthy Participants

A Phase 1 interventional study of 14C Tirzepatide in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-24.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
30 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to look at how much tirzepatide gets into the bloodstream and how long the body takes to get rid of it. This study will involve a single dose of 14C radiolabelled tirzepatide. This means that a radioactive tracer substance, C14, will be incorporated into the study drug to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine, feces and expired air.

Screening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be approximately 15 weeks, including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy males as determined by medical history, physical examination, and other screening procedures
  • Have a (BMI) between 18.0 to 32.0 kilograms per meter squared (kg/m²), inclusive at screening
  • Are willing to be available for the full duration of the study

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to tirzepatide or related compounds
  • Have a medical condition or medical history that makes participation in the study unsafe or which may interfere in the interpretation of the results of the study
  • Have had exposure to significant radiation within 12 months prior to dosing (for example, multiple x-ray or computed tomography [CT] scans, barium meal, being employed in a job requiring radiation exposure monitoring)
  • Have participated in any clinical trial involving a radiolabeled substance within the past 12 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    14C Tirzepatide

    A single dose of \[14C\]-tirzepatide administered subcutaneously (SC).

    Drug: 14C Tirzepatide

Interventions

06

What researchers measure

Primary outcomes

  1. Urinary Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered

    Urinary Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered.

    Time frame: Pre-dose and up to 63 days post-dose

  2. Fecal Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered

    Fecal Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered.

    Time frame: Pre-dose and up to 63 days post-dose

Secondary outcomes

  1. Total Number of Metabolites

    Total Number of Metabolites.

    Time frame: Pre-dose and up to 63 days post-dose

  2. Total Radioactivity Recovered in Urine, Feces, and Expired Air (if Applicable)

    Total Radioactivity Recovered in Urine, Feces, and Expired Air (if Applicable).

    Time frame: Pre-dose and up to 63 days post-dose

  3. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC[0-∞]) of Tirzepatide

    Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC\[0-∞\]) of tirzepatide.

    Time frame: Pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 10, 12, 14, 22, 29, 36, 43, 50, 57, and 64 post dose

  4. PK: Maximum Concentration (Cmax) of Tirzepatide

    PK: Maximum Concentration (Cmax) of tirzepatide.

    Time frame: Pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 10, 12, 14, 22, 29, 36, 43, 50, 57, and 64 post dose

  5. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC[0-∞]) of Total Radioactivity

    Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC\[0-∞\]) of Total Radioactivity. Total radioactivity is reported as hours\*nanogram equivalents per milliliter (h\*ng Eq/mL).

    Time frame: Pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 10, 12, 14, 22, 29, 36, 43, 50, 57, and 64 post dose

  6. PK: Maximum Concentration (Cmax) of Total Radioactivity

    PK: Cmax of total radioactivity in plasma and whole blood. The Cmax of total radioactivity in plasma and whole blood are reported as nanogram equivalents per milliliter (ng Eq/mL).

    Time frame: Pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 10, 12, 14, 22, 29, 36, 43, 50, 57, and 64 post dose

07

Results

Posted Mar 24, 2023

Participant flow

Participant flow — Overall Study
Milestone[14C]-Tirzepatide
Started6
Completed6
Not completed0

Outcome measures

PrimaryUrinary Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered

Urinary Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered.

Time frame:
Pre-dose and up to 63 days post-dose
Reported as:
Mean · Percentage of the total radioactive dose
Urinary Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered
Percentage of the total radioactive dose[14C]-Tirzepatide
Urinary Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered49.56 ± 2.58
PrimaryFecal Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered

Fecal Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered.

Time frame:
Pre-dose and up to 63 days post-dose
Reported as:
Mean · Percentage of the total radioactive dose
Fecal Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered
Percentage of the total radioactive dose[14C]-Tirzepatide
Fecal Excretion of Tirzepatide Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered20.46 ± 2.05
SecondaryTotal Number of Metabolites

Total Number of Metabolites.

Time frame:
Pre-dose and up to 63 days post-dose
Reported as:
Number · metabolites
Total Number of Metabolites
metabolites[14C]-Tirzepatide
Plasma4
Urine6
Feces6
SecondaryTotal Radioactivity Recovered in Urine, Feces, and Expired Air (if Applicable)

Total Radioactivity Recovered in Urine, Feces, and Expired Air (if Applicable).

Time frame:
Pre-dose and up to 63 days post-dose
Reported as:
Mean · Percentage of the total radioactive dose
Total Radioactivity Recovered in Urine, Feces, and Expired Air (if Applicable)
Percentage of the total radioactive dose[14C]-Tirzepatide
Total Radioactivity Recovered in Urine, Feces, and Expired Air (if Applicable)70.03 ± 1.98
SecondaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC[0-∞]) of Tirzepatide

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC\[0-∞\]) of tirzepatide.

Time frame:
Pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 10, 12, 14, 22, 29, 36, 43, 50, 57, and 64 post dose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC[0-∞]) of Tirzepatide
nanogram*hour per milliliter (ng*h/mL)[14C]-Tirzepatide
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC[0-∞]) of Tirzepatide96100 ± 13
SecondaryPK: Maximum Concentration (Cmax) of Tirzepatide

PK: Maximum Concentration (Cmax) of tirzepatide.

Time frame:
Pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 10, 12, 14, 22, 29, 36, 43, 50, 57, and 64 post dose
Reported as:
Geometric mean · ng/mL
PK: Maximum Concentration (Cmax) of Tirzepatide
ng/mL[14C]-Tirzepatide
PK: Maximum Concentration (Cmax) of Tirzepatide453 ± 29
SecondaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC[0-∞]) of Total Radioactivity

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC\[0-∞\]) of Total Radioactivity. Total radioactivity is reported as hours\*nanogram equivalents per milliliter (h\*ng Eq/mL).

Time frame:
Pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 10, 12, 14, 22, 29, 36, 43, 50, 57, and 64 post dose
Reported as:
Geometric mean · h*ng Eq/mL
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) From Zero To Infinity (AUC[0-∞]) of Total Radioactivity
h*ng Eq/mL[14C]-Tirzepatide
Plasma87900 ± 13
Whole blood44000 ± 11
SecondaryPK: Maximum Concentration (Cmax) of Total Radioactivity

PK: Cmax of total radioactivity in plasma and whole blood. The Cmax of total radioactivity in plasma and whole blood are reported as nanogram equivalents per milliliter (ng Eq/mL).

Time frame:
Pre-dose, Day 1, 2, 3, 4, 5, 6, 7, 10, 12, 14, 22, 29, 36, 43, 50, 57, and 64 post dose
Reported as:
Geometric mean · ng Eq/mL
PK: Maximum Concentration (Cmax) of Total Radioactivity
ng Eq/mL[14C]-Tirzepatide
Plasma327 ± 16
Whole Blood173 ± 14

Adverse events

Collected over Up To Day 64. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
[14C]-Tirzepatide0/6 (0%)0/6 (0%)6/6 (100%)
Most frequent other events
Most frequent other events
Event[14C]-Tirzepatide
Decreased appetiteMetabolism and nutrition disorders6/6
PalpitationsCardiac disorders2/6
NauseaGastrointestinal disorders1/6
ToothacheGastrointestinal disorders1/6
VomitingGastrointestinal disorders1/6
Feeling of body temperature changeGeneral disorders1/6
PresyncopeNervous system disorders1/6

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)[14C]-Tirzepatide
Mean41.0 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)[14C]-Tirzepatide
Female0
Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)[14C]-Tirzepatide
Hispanic or Latino0
Not Hispanic or Latino6
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)[14C]-Tirzepatide
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White6
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)[14C]-Tirzepatide
United Kingdom6
08

Study locations

1 site
  • Covance Clinical Research Ltd
    Leeds, West Yorkshire LS2 9LH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Oct 2020, 2 months.

Results were first posted in Mar 2023, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2020
First posted
Mar 17, 2020
StartActual
Jul 28, 2020
Primary completionActual
Oct 2, 2020
CompletionActual
Oct 2, 2020
Results first posted
Mar 24, 2023
Last update
Mar 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04311424
Responsible party
Sponsor
First posted
Mar 17, 2020
Start date
Jul 28, 2020
Primary completion
Oct 2, 2020
Completion
Oct 2, 2020
Results posted
Mar 24, 2023
Last update
Mar 24, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion